However, the FDA will respond to public health emergencies involving FDA-regulated products. Furthermore, domestic for-cause inspection assignments are evaluated and proceed in cases where decisions are mission-critical. During this interim period, other ways to conduct inspectional work will be explored, such as evaluating records instead of on-site inspections. The FDA calls upon the responsibility of manufacturers to produce reliable quality products according to cGMP requirements.
> Do not hesitate, we look forward to your feedback!
Write a comment on this news.